ArticleBreast cancer (Tokyo, Japan)2026
Overall survival of patients with second primary breast cancer associated with molecular subtype and epidemiological profile at a cancer center.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bilateral Primary Breast Cancer: Current Evidence and Future Perspectives.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most prevalent cancer diagnosed in women in 2022 was breast cancer, with an estimated 2.26 million new cases worldwide. Among women with breast cancer, second primary breast carcinoma is the most common malignancy. The present study aimed to analyze the overall survival of second primary breast cancer patients at a cancer center.
methodsA retrospective cohort study of women with second primary breast cancer, diagnosed between 2000 and 2015, was conducted. The cases were drawn from the Hospital Cancer Registry (HCR) and second primary breast cancer was classified according to the rules for these cancers. Survival curves were estimated using the Kaplan-Meier method.
resultsA total of 11.922 women with breast cancer were identified between 2000 and 2015. Of these, 3.24% (375) had second primary breast cancer, comprising 60.8% (228) synchronous and 39.2% (147) metachronous tumors. The 5-year survival rate was 86.5% (CI 79.69-91.21%) for women with synchronous breast cancer and 82.1% (CI 73.71-88.10%) for metachronous cancer cases. Both groups had a 10-year survival rate of 69%.
conclusionOverall survival of patients with second primary breast cancer was similar for both synchronous and metachronous tumors. Second primary tumors in this cohort appeared to occur sporadically, as patients were predominantly over 50 years of age with luminal B phenotype in the contralateral breast. Future studies should investigate the presence of associated genetic syndromes in these patients.
Indexed as
Identifiers
41258585What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.